Novel population pharmacokinetic model for Linezolid in critically Ill patients and evaluation of the adequacy of the current dosing recommendation
Antimicrobial treatment in critically ill patients remains challenging. The aim of this study was to develop a population pharmacokinetic model for linezolid in critically ill patients and to evaluate the adequacy of current dosing recommendation (600 mg/12 h). Forty inpatients were included, 23 of...
| Autores: | , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2020 |
| País: | España |
| Institución: | Universidad de Navarra |
| Repositorio: | Dadun. Depósito Académico Digital de la Universidad de Navarra |
| Idioma: | inglés |
| OAI Identifier: | oai:dadun.unav.edu:10171/67194 |
| Acceso en línea: | https://hdl.handle.net/10171/67194 |
| Access Level: | acceso abierto |
| Palabra clave: | Linezolid Population pharmacokinetics Critically ill Continuous renal replacement therapies Pharmacokinetic/pharmacodynamics Continuous infusion |
| id |
ES_b2f06f045c6dd2fa35f0efef5297d411 |
|---|---|
| oai_identifier_str |
oai:dadun.unav.edu:10171/67194 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Novel population pharmacokinetic model for Linezolid in critically Ill patients and evaluation of the adequacy of the current dosing recommendationSoraluce, A. (Amaia)|||/items/91ae532a-483d-40fa-8379-a0b9a6bc47e5Barrasa, H. (Helena)|||/items/06d7a775-f7af-461e-82d2-7458e792ac0cPrieto, E. (Eduardo)|||/items/6194baa9-5f4e-4efe-9c83-a810e3737ae6Sanchez-Izquierdo, J.A. (José Ángel)|||/items/812d5624-adfa-403c-bf62-abba25028983Maynar, J. (Javier)|||/items/40888cae-cd41-454a-8245-251c825183d6Isla, A. (Arantxazu)|||/items/7d611dfc-94a7-4ab1-b2b2-f8cde49e3ff2Rodriguez-Gascón, A. (Alicia)|||/items/c50ffa2a-e017-4cbe-90f8-6ccabc924f31LinezolidPopulation pharmacokineticsCritically illContinuous renal replacement therapiesPharmacokinetic/pharmacodynamicsContinuous infusionAntimicrobial treatment in critically ill patients remains challenging. The aim of this study was to develop a population pharmacokinetic model for linezolid in critically ill patients and to evaluate the adequacy of current dosing recommendation (600 mg/12 h). Forty inpatients were included, 23 of whom were subjected to continuous renal replacement therapies (CRRT). Blood and effluent samples were drawn after linezolid administration at defined time points, and linezolid levels were measured. A population pharmacokinetic model was developed, using NONMEM 7.3. The percentage of patients that achieved the pharmacokinetic/pharmacodynamic (PK/PD) targets was calculated (AUC24/MIC > 80 and 100% T>MIC). A two-compartment model best described the pharmacokinetics of linezolid. Elimination was conditioned by the creatinine clearance and by the extra-corporeal clearance if the patient was subjected to CRRT. For most patients, the standard dose of linezolid did not cover infections caused by pathogens with MIC ≥ 2 mg/L. Continuous infusion may be an alternative, especially when renal function is preserved.MDPI AGDadun. Depósito Académico Digital Universidad de Navarra20232023-08-3120202020-01-0120202020-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/67194reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/671942026-06-21T12:47:57Z |
| dc.title.none.fl_str_mv |
Novel population pharmacokinetic model for Linezolid in critically Ill patients and evaluation of the adequacy of the current dosing recommendation |
| title |
Novel population pharmacokinetic model for Linezolid in critically Ill patients and evaluation of the adequacy of the current dosing recommendation |
| spellingShingle |
Novel population pharmacokinetic model for Linezolid in critically Ill patients and evaluation of the adequacy of the current dosing recommendation Soraluce, A. (Amaia)|||/items/91ae532a-483d-40fa-8379-a0b9a6bc47e5 Linezolid Population pharmacokinetics Critically ill Continuous renal replacement therapies Pharmacokinetic/pharmacodynamics Continuous infusion |
| title_short |
Novel population pharmacokinetic model for Linezolid in critically Ill patients and evaluation of the adequacy of the current dosing recommendation |
| title_full |
Novel population pharmacokinetic model for Linezolid in critically Ill patients and evaluation of the adequacy of the current dosing recommendation |
| title_fullStr |
Novel population pharmacokinetic model for Linezolid in critically Ill patients and evaluation of the adequacy of the current dosing recommendation |
| title_full_unstemmed |
Novel population pharmacokinetic model for Linezolid in critically Ill patients and evaluation of the adequacy of the current dosing recommendation |
| title_sort |
Novel population pharmacokinetic model for Linezolid in critically Ill patients and evaluation of the adequacy of the current dosing recommendation |
| dc.creator.none.fl_str_mv |
Soraluce, A. (Amaia)|||/items/91ae532a-483d-40fa-8379-a0b9a6bc47e5 Barrasa, H. (Helena)|||/items/06d7a775-f7af-461e-82d2-7458e792ac0c Prieto, E. (Eduardo)|||/items/6194baa9-5f4e-4efe-9c83-a810e3737ae6 Sanchez-Izquierdo, J.A. (José Ángel)|||/items/812d5624-adfa-403c-bf62-abba25028983 Maynar, J. (Javier)|||/items/40888cae-cd41-454a-8245-251c825183d6 Isla, A. (Arantxazu)|||/items/7d611dfc-94a7-4ab1-b2b2-f8cde49e3ff2 Rodriguez-Gascón, A. (Alicia)|||/items/c50ffa2a-e017-4cbe-90f8-6ccabc924f31 |
| author |
Soraluce, A. (Amaia)|||/items/91ae532a-483d-40fa-8379-a0b9a6bc47e5 |
| author_facet |
Soraluce, A. (Amaia)|||/items/91ae532a-483d-40fa-8379-a0b9a6bc47e5 Barrasa, H. (Helena)|||/items/06d7a775-f7af-461e-82d2-7458e792ac0c Prieto, E. (Eduardo)|||/items/6194baa9-5f4e-4efe-9c83-a810e3737ae6 Sanchez-Izquierdo, J.A. (José Ángel)|||/items/812d5624-adfa-403c-bf62-abba25028983 Maynar, J. (Javier)|||/items/40888cae-cd41-454a-8245-251c825183d6 Isla, A. (Arantxazu)|||/items/7d611dfc-94a7-4ab1-b2b2-f8cde49e3ff2 Rodriguez-Gascón, A. (Alicia)|||/items/c50ffa2a-e017-4cbe-90f8-6ccabc924f31 |
| author_role |
author |
| author2 |
Barrasa, H. (Helena)|||/items/06d7a775-f7af-461e-82d2-7458e792ac0c Prieto, E. (Eduardo)|||/items/6194baa9-5f4e-4efe-9c83-a810e3737ae6 Sanchez-Izquierdo, J.A. (José Ángel)|||/items/812d5624-adfa-403c-bf62-abba25028983 Maynar, J. (Javier)|||/items/40888cae-cd41-454a-8245-251c825183d6 Isla, A. (Arantxazu)|||/items/7d611dfc-94a7-4ab1-b2b2-f8cde49e3ff2 Rodriguez-Gascón, A. (Alicia)|||/items/c50ffa2a-e017-4cbe-90f8-6ccabc924f31 |
| author2_role |
author author author author author author |
| dc.contributor.none.fl_str_mv |
Dadun. Depósito Académico Digital Universidad de Navarra |
| dc.subject.none.fl_str_mv |
Linezolid Population pharmacokinetics Critically ill Continuous renal replacement therapies Pharmacokinetic/pharmacodynamics Continuous infusion |
| topic |
Linezolid Population pharmacokinetics Critically ill Continuous renal replacement therapies Pharmacokinetic/pharmacodynamics Continuous infusion |
| description |
Antimicrobial treatment in critically ill patients remains challenging. The aim of this study was to develop a population pharmacokinetic model for linezolid in critically ill patients and to evaluate the adequacy of current dosing recommendation (600 mg/12 h). Forty inpatients were included, 23 of whom were subjected to continuous renal replacement therapies (CRRT). Blood and effluent samples were drawn after linezolid administration at defined time points, and linezolid levels were measured. A population pharmacokinetic model was developed, using NONMEM 7.3. The percentage of patients that achieved the pharmacokinetic/pharmacodynamic (PK/PD) targets was calculated (AUC24/MIC > 80 and 100% T>MIC). A two-compartment model best described the pharmacokinetics of linezolid. Elimination was conditioned by the creatinine clearance and by the extra-corporeal clearance if the patient was subjected to CRRT. For most patients, the standard dose of linezolid did not cover infections caused by pathogens with MIC ≥ 2 mg/L. Continuous infusion may be an alternative, especially when renal function is preserved. |
| publishDate |
2020 |
| dc.date.none.fl_str_mv |
2020 2020-01-01 2020 2020-01-01 2023 2023-08-31 |
| dc.type.none.fl_str_mv |
journal article http://purl.org/coar/resource_type/c_6501 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/10171/67194 |
| url |
https://hdl.handle.net/10171/67194 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
MDPI AG |
| publisher.none.fl_str_mv |
MDPI AG |
| dc.source.none.fl_str_mv |
reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra instname:Universidad de Navarra |
| instname_str |
Universidad de Navarra |
| reponame_str |
Dadun. Depósito Académico Digital de la Universidad de Navarra |
| collection |
Dadun. Depósito Académico Digital de la Universidad de Navarra |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869417096650162176 |
| score |
15.301603 |